Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2770)	8/9/2010 11:28:09 AM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

ISPH is trying to move up from the $5 level.<g> The stock was up 5% at 10:38am but is up only 3.31% at present. Volume is low, > 1/10 its ADV bigcharts.marketwatch.com ISPH has continued to report better revenues and to trim its losses. ISPH focus is in the two specialty pharmaceutical markets: Ophthalmology, anchored by their AzaSite and supported by a portfolio of revenue-generating products. And Pulmonology, anchored by denufosol, their potential breakthrough product for cystic fibrosis. It reported its 2ndQ results and had a CC last week. This is a transcription of the CC by S.A.: seekingalpha.com The ACTAY is $10.33 But it seems better to wait for further developments and for the stock to be able to close above $6 <g> bigcharts.marketwatch.com However, with some good reports, the $10 could be doable.<g> bigcharts.marketwatch.com Bernard